A growth hormone that can be administered once weekly was approved in Korea.

The Ministry of Food and Drug Safety approved Novo Nordisk’s ‘Sogroya Prefilled Pen (somapacitan-beco)’ 5mg, 10mg, and 15mg on June 6.

Sogroya is a once-weekly treatment for adult hormone deficiency and is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and in adults with growth hormone deficiency (adult GHD) in Korea.

As a type of human growth hormone analogue that is injected subcutaneously once a week, Sogroya offers better dosage convenience over existing growth hormone formulations that require daily dosing.

The dru